Latest Breaking News On - Smilow - Page 1 : comparemela.com

TAGRISSO Approved in the US for the Adjuvant Treatment of Patients With Early-Stage EGFR-mutated Lung Cancer Approval based on unprecedented results from the ADAURA Phase III trial where TAGRISSO WILMINGTON, Del. (BUSINESS WIRE) AstraZeneca’s TAGRISSO ® (osimertinib) has been approved in the US for the adjuvant treatment of adult patients with early-stage epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC) after tumor resection with curative intent. TAGRISSO is indicated for EGFRm patients whose tumors have exon 19 deletions or exon 21 L858R mutations as detected by an approved test. The approval was granted under the US Food and Drug Administration’s (FDA) Real-Time Oncology Review (RTOR) pilot program. Five other countries participated in a concurrent submission and review process through FDA’s Project Orbis.

United statesUnited kingdomDave fredricksonRoys herbstLe chevalierAmerican society of clinical oncologyOncology centerSingapore health sciences authorityOncology at yale cancer centerInternational agency for research on cancerCollaborative groupSingle institution studyArch pathol labDrug administrationWorld health organizationData monitoring committee